SCHEMBL30977339

SCHEMBL30977339

CC(C)Oc1ccc2ccnn2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.38
DRD4 P21917 2/20 0.38
DRD3 P35462 2/20 0.38
DRD1 P21728 1/20 0.38
HTR2A P28223 1/20 0.38
WDR5 P61964 2/20 0.36
KMT2A Q03164 3/20 0.36
BMPR1B O00238 1/20 0.36
ACVR1B P36896 1/20 0.36
ACVRL1 P37023 1/20 0.36
ACVR1 Q04771 1/20 0.36
TP53 P04637 2/20 0.35
MAPT P10636 1/20 0.35
ALDH1A3 P47895 1/20 0.35
FGFR1 P11362 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
ALDH1A1 P00352 3/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30977412 0.82 RXRA (0.36) DRD2DRD4DRD3DRD1HTR2A
SCHEMBL18338474 0.79 DRD2 (0.45) DRD2DRD4DRD3DRD1HTR2A
SCHEMBL30175354 0.78 DRD2 (0.43) DRD2DRD4DRD3DRD1HTR2A
SCHEMBL25421011 0.75 DRD2 (0.45) DRD2DRD4DRD3DRD1HTR2A
SCHEMBL25061842 0.74 SCN5A (0.43) DRD2DRD4DRD3DRD1HTR2A
SCHEMBL29786198 0.72 ACACB (0.38) DRD2DRD4DRD3DRD1HTR2A
SCHEMBL30496653 0.71 DRD2 (0.43) DRD2DRD4DRD3DRD1HTR2A
SCHEMBL24567001 0.71 DRD2 (0.54) DRD2DRD4DRD3DRD1HTR2A
SCHEMBL25416514 0.70 KDR (0.47) BMPR1BACVR1BACVRL1ACVR1ALDH1A3
SCHEMBL4968862 0.70 DRD2 (0.34) DRD2DRD4DRD3DRD1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4619402-A1 GPR17 MODULATORS AND USES THEREOF Myrobalan Therapeutics, Inc. (US) 2025-09-24 EP disclosed
CN-119613397-A N-heteroaromatic ring-3-sulfonamide compounds and use thereof for preparing GPR17 receptor inhibitors 迈巴制药(南京)有限公司 2025-03-14 CN disclosed
WO-2024104462-A1 GPR17 MODULATORS AND USES THEREOF MYROBALAN THERAPEUTICS NANJING CO. LTD (CN) 2024-05-23 WO disclosed